Durvalumab is a human anti-PD-L1 IgG1-K monoclonal antibody approved by the FDA for locally advanced or metastatic urothelial cancer and locally advanced, unresectable, stage 3 non-small cell lung cancer; Karzai et al. [56] found that olaparib (PARPi) plus durvalumab demonstrated activity in PC patients without biallelic inactivation of DDR pathways, reaching deep responses in mutated cases: this drug combination revealed acceptable toxicity and efficacy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.